HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Nuvectis Pharma (NASDAQ:NVCT) with a maintained price target of $21.
May 08, 2024 | 7:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nuvectis Pharma receives a reiterated Buy rating and a maintained $21 price target from HC Wainwright & Co.
The reiteration of a Buy rating and the maintenance of a $21 price target by a reputable analyst firm like HC Wainwright & Co. can positively influence investor sentiment towards NVCT. This endorsement may lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100